1,25-Dihydroxyvitamin D3 Treatment Shrinks Uterine Leiomyoma Tumors in the Eker Rat Model

Biology of Reproduction

Volumn 86, Issue 4, 2012, Pages

  Halder, Sunil K ^a   Sharan, Chakradhari ^a   Al Hendy, Ayman ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

1,25 dihydroxyvitamin D3; Eker rats; Fibroids; Leiomyoma; Radioimmunoassay

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCITRIOL; CALCIUM ION; CASPASE 3; ESTROGEN RECEPTOR; ETHYLENE GLYCOL; PROGESTERONE RECEPTOR; VITAMIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BCL2 GENE; BCL2L1 GENE; CDK1 GENE; CDK2 GENE; CDK4 GENE; CONTROLLED STUDY; CYCLIN D1 GENE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; ONCOGENE MYC; PCNA GENE; PRIORITY JOURNAL; RAT; TUMOR VOLUME; UTERUS MYOMA; VITAMIN D DEFICIENCY; ANIMAL; CELL GROWTH; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETICS; LEIOMYOMA; PATHOLOGY; UTERUS CANCER;

RATTUS;

ANIMALS; CALCITRIOL; CELL GROWTH PROCESSES; DISEASE MODELS, ANIMAL; FEMALE; LEIOMYOMA; RATS; TUMOR BURDEN; UTERINE NEOPLASMS; VITAMINS;

EID: 84864017713     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.111.098145     Document Type: Article

References (70)

1. Maruo T, Matsuo H, Samoto T, Shimomura Y, Kurachi O, Gao Z, Wang Y, Spitz IM, Johansson E. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000; 65:585-592.
2. Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI, Fuchs-Young R. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig 2000; 7:249-256.
3. Stewart EA. Uterine fibroids. Lancet 2001; 357:293-298.
4. Farhi J, Ashkenazi J, Feldberg D, Dicker D, Orvieto R, Ben Rafael Z. Effect of uterine leiomyomata on the results of in-vitro fertilization treatment. Hum Reprod 1995; 10:2576-2578.
5. Surrey ES, Lietz AK, Schoolcraft WB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilizationembryo transfer cycle outcome. Fertil Steril 2001; 75:405-410.
6. Eldar-Geva T, Meagher S, Healy DL, MacLachlan V, Breheny S, Wood C. Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted reproductive technology treatment. Fertil Steril 1998; 70:687-691.
7. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994; 83: 549-555.
8. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308:1589-1592.
9. Bachmann G. Expanding treatment options for women with symptomatic uterine leiomyomas: timely medical breakthroughs. Fertil Steril 2006; 85: 46-47; discussion 48-50.
10. Lefebvre G, Allaire C, Jeffrey J, Vilos G, Arneja J, Birch C, Fortier M. SOGC clinical guidelines. Hysterectomy. J Obstet Gynaecol Can 2002; 24:37-61; quiz 74-76.
11. Stein K, Ascher-Walsh C. A comprehensive approach to the treatment of uterine leiomyomata. Mt Sinai J Med 2009; 76:546-556.
12. Al-Hendy A, Salama S. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update 2006; 12:385-400.
13. Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecol Laparosc 1998; 5:289-292.
14. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol 1980; 55:20-24.
15. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995; 172:14-18.
16. Parazzini F, Negri E, La Vecchia C, Chatenoud L, Ricci E, Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology 1996; 7: 440-442.
17. Benassayag C, Leroy MJ, Rigourd V, Robert B, Honore JC, Mignot TM, Vacher-Lavenu MC, Chapron C, Ferre F. Estrogen receptors (ERalpha/ ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol 1999; 276:E1112-E1118.
18. Wang Y, Matsuo H, Kurachi O, Maruo T. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol 2002; 146:447-456.
19. Al-Hendy A, Salama SA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 2006; 86:686-693.
20. Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, Erickson TE, Warner C, Keenan EJ, Clinton GM. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993; 169:78-85.
21. Brandon DD, Erickson TE, Keenan EJ, Strawn EY, Novy MJ, Burry KA, Warner C, Clinton GM. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 1995; 80:1876-1881.
22. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003; 14:247-250.
23. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Doughertly C, Gunter EW, Bowman BA. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002; 76:187-192.
24. Holick MF. Too little vitamin D in premenopausal women: why should we care? Am J Clin Nutr 2002; 76:3-4.
25. Ylikomi T, Laaksi I, Lou YR, Martikainen P, Miettinen S, Pennanen P, Purmonen S, Syvälä H, Vienonen A, Tuohimaa P. Antiproliferative action of vitamin D. Vitam Horm 2002; 64:357-406.
26. Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 1999; 59:4848-4856.
27. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997; 57: 3759-3764.
28. Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-Omethyltransferase. Fertil Steril 95:247-253.
29. Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 96:E754-E762.
30. Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 2009; 200:207-221.
31. Bläuer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril 2009; 91:1919-1925.
32. James SY, Mercer E, Brady M, Binderup L, Colston KW. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 1998; 125:953-962.
33. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker C. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol 1995; 146:1556-1567.
34. Hassan MH, Salama SA, Zhang D, Arafa HM, Hamada FM, Fouad H, Walker CC, Al-Hendy A. Gene therapy targeting leiomyoma: adenovirusmediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril 2010; 93:239-250.
35. Sbrana E, Xiao SY, Popov VL, Newman PC, Tesh RB. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am J Trop Med Hyg 2006; 74:1084-1089.
36. Pourgholami MH, Akhter J, Lu Y, Morris DL. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett 2000; 151:97-102.
37. Al-Hendy A, Auersperg N. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drugsensitization system. Gynecol Obstet Invest 1997; 43:268-275.
38. Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res 2005; 307:231-246.
39. Hollis BW. Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. Methods Enzymol 1997; 282:174-186.
40. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7:812-821.
41. Jeffers MD, Richmond JA, Macaulay EM. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas. Mod Pathol 1995; 8:701-704.
42. Chegini N, Verala J, Luo X, Xu J, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig 2003; 10:161-171.
43. Al-Hendy A, Lee EJ, Wang HQ, Copland JA. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 2004; 191:1621-1631.
44. Catherino WH, Leppert PC, Stenmark MH, Payson M, Potlog-Nahari C, Nieman LK, Segars JH. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 2004; 40:204-217.
45. Tsibris JC, Segars J, Coppola D, Mane S, Wilbanks GD, O'Brien WF, Spellacy WN. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 2002; 78:114-121.
46. Stewart EA, Friedman AJ, Peck K, Nowak RA. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 1994; 79:900-906.
47. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/ extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 2004; 89: 5549-5557.
48. Downes E, Sikirica V, Gilabert-Estelles J, Bolge SC, Dodd SL, Maroulis C, Subramanian D. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol 2010; 152:96-102.
49. Mauskopf J, Flynn M, Thieda P, Spalding J, Duchane J. The economic impact of uterine fibroids in the United States: a summary of published estimates. J Womens Health (Larchmt) 2005; 14:692-703.
50. Martel KM, Ko AC, Christman GM, Stribley JM. Apoptosis in human uterine leiomyomas. Semin Reprod Med 2004; 22:91-103.
51. Halder SK, Sharan C, Harirah H, Al-Hendy A. Lower serum levels of vitamin D3 is a risk factor for uterine fibroids in African Americans. Presented at the 57th Annual Scientific Meeting, Society of Gynecologic Investigation (SGI), March 24-27, 2010, Orlando, Florida.
52. Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, Hewison M. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J 2011; 25: 937-947.
53. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 2000; 46:2027-2049.
54. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-F175.
55. Hoenderop JG, Mü ller D, Van Der Kemp AW, Hartog A, Suzuki M, Ishibashi K, Imai M, Sweep F, Willems PH, Van Os CH, Bindels RJ. Calcitriol controls the epithelial calcium channel in kidney. J Am Soc Nephrol 2001; 12:1342-1349.
56. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290-2298.
57. Holick MF. Vitamin D: a millenium perspective. J Cell Biochem 2003; 88: 296-307.
58. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85:6-18.
59. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77:204-210.
60. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73:288-294.
61. Dietary Reference Intake Tables, Health Canada, 2005. World Wide Web (URL: http://dietarysupplementdatabase.usda.nih.gov/ingredient_ calculator/help.php#q9). (July 21, 2011).
62. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96:252-261.
63. Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC, Robboy SJ. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch 2002; 441: 53-62.
64. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986; 166:209-219.
65. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 2002; 78:1-12.
66. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. Mechanisms of estrogen action. Physiol Rev 2001; 81:1535-1565.
67. Li HJ, Haque Z, Lu Q, Li L, Karas R, Mendelsohn M. Steroid receptor coactivator 3 is a coactivator for myocardin, the regulator of smooth muscle transcription and differentiation. Proc Natl Acad Sci U S A 2007; 104:4065-4070.
68. Hussein-Fikret S, Fuller PJ, Gargett CE. Expression of steroid receptor coactivators in cultured cells from paired myometrial and fibroid tissues. J Soc Gynecol Investig 2005; 12:445-451.
69. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994; 331:1618-1623.
70. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-691.